WSR 21-22-062
[Filed October 28, 2021, 3:38 p.m.]
Original Notice.
Preproposal statement of inquiry was filed as WSR 21-18-067.
Title of Rule and Other Identifying Information: WAC 182-532-530 Family planning only programsCovered services; other related rules as appropriate.
Hearing Location(s): On December 7, 2021, at 10:00 a.m. The health care authority (HCA) remains closed in response to the coronavirus disease 2019 (COVID-19) public health emergency. Until further notice, HCA continues to hold public hearings virtually without a physical meeting place. This promotes social distancing and the safety of the residents of Washington state. To attend the virtual public hearing, you must register in advance for this public hearing After registering, you will receive a confirmation email containing information about joining the public hearing.
Date of Intended Adoption: Not sooner than December 8, 2021.
Submit Written Comments to: HCA Rules Coordinator, P.O. Box 42716, Olympia, WA 98504-2716, email, fax 360-586-9727, by December 7, 2021.
Assistance for Persons with Disabilities: Contact HCA Rules Coordinator, phone 360-725-1306, fax 360-586-9727, telecommunication[s] relay service 711, email, by November 19, 2021.
Purpose of the Proposal and Its Anticipated Effects, Including Any Changes in Existing Rules: The agency is amending this rule to add the HPV vaccine as a covered service under the family planning only program.
Reasons Supporting Proposal: See purpose.
Statutory Authority for Adoption: RCW 41.05.021, 41.05.160.
Statute Being Implemented: RCW 41.05.021, 41.05.160.
Rule is not necessitated by federal law, federal or state court decision.
Agency Comments or Recommendations, if any, as to Statutory Language, Implementation, Enforcement, and Fiscal Matters: Not applicable.
Name of Proponent: HCA, governmental.
Name of Agency Personnel Responsible for Drafting: Valerie Freudenstein, P.O. Box 42716, Olympia, WA 98504-2716, 360-725-1344; Implementation and Enforcement: Melissa Kundur, P.O. Box 55109, Olympia, WA 98504-5109, 360-725-5297.
A school district fiscal impact statement is not required under RCW 28A.305.135.
A cost-benefit analysis is not required under RCW 34.05.328. RCW 34.05.328 does not apply to HCA rules unless requested by the joint administrative rules review committee or applied voluntarily.
The proposed rule does not impose more-than-minor costs on businesses. Following is a summary of the agency's analysis showing how costs were calculated. The proposed rule does not impose any costs on businesses.
October 28, 2021
Wendy Barcus
Rules Coordinator
AMENDATORY SECTION(Amending WSR 19-18-024, filed 8/28/19, effective 10/1/19)
WAC 182-532-530Family planning only programsCovered services.
The medicaid agency covers all of the following services:
(1) One comprehensive preventive family planning visit once every twelve months, based on nationally recognized clinical guidelines. This visit must have a primary focus and diagnosis of family planning and include counseling, education, risk reduction, and initiation or management of contraceptive methods;
(2) Assessment and management of family planning or contraceptive problems, when medically necessary;
(3) Contraception, including:
(a) Food and Drug Administration (FDA)-approved contraceptive methods, as described under WAC 182-530-2000;
(b) Education and supplies for Federal Drug Administration (FDA)-approved contraceptive, natural family planning, and abstinence; and
(c) Sterilization procedures, as described under WAC 182-531-1550.
(4) The following services, when appropriate, during a visit focused on family planning:
(a) Pregnancy testing;
(b) Cervical cancer screening, according to nationally recognized clinical guidelines;
(c) Gonorrhea and chlamydia screening and treatment for clients age thirteen through twenty-five, according to nationally recognized clinical guidelines;
(d) Syphilis screening and treatment for clients who have an increased risk for syphilis, according to nationally recognized guidelines; and
(e) Sexually transmitted infection (STI) screening, testing, and treatment, when medically indicated by symptoms or report of exposure, and medically necessary for the client's safe and effective use of their chosen contraceptive method.
(5) Human papillomavirus (HPV) vaccines.